Comparative Pharmacology
Head-to-head clinical analysis: IMPLANON versus INCASSIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPLANON versus INCASSIA.
IMPLANON vs INCASSIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Etonogestrel, a progestin, binds to progesterone and androgen receptors, suppressing gonadotropin release (FSH, LH) and preventing ovulation. It also increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial morphology.
INCASSIA (bleomycin) is an antineoplastic antibiotic that causes DNA strand breaks through free radical generation, inhibiting DNA synthesis and cell division.
Insert 1 rod (68 mg etonogestrel) subdermally in the inner upper arm; replacement every 3 years.
1.5 mg orally once daily, administered with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 25-30 hours; significant interindividual variability
Terminal elimination half-life is 8-12 hours in adults with normal renal function. This supports twice-daily dosing, though dose adjustment is required in renal impairment (CrCl <30 mL/min).
Metabolites primarily excreted in urine (approximately 50%) and feces (30-35%)
Renal excretion of unchanged drug accounts for approximately 60-70% of the administered dose, with biliary/fecal elimination contributing about 20-30%. Less than 10% is metabolized.
Category C
Category C
Contraceptive
Contraceptive